ALTRAZEAL Press Releases

03/23/2011

ULURU INC. ANNOUNCES THE GRANTING OF ALTRAZEAL® PATENT

Addison, Texas, March 23, 2011; ULURU Inc. (NYSE AMEX: ULU) announced today that it has been issued U.S. Patent 7,910,135 - Hydrogel Wound Dressing and Biomaterials Formed In Situ and Their Uses. This patent provides additional coverage for Altrazeal® and, including The Patent Term Adjustment granted by the U.S. Patent and Trademark Office, extends patent coverage on Altrazeal® until January 2029. Read More

01/19/2011

ULURU INC. ANNOUNCES AGREEMENT WITH EXCITON TO DEVELOP ANTIMICROBIAL DRESSING

Addison, Texas, January 19, 2010; ULURU Inc. (NYSE Alternext: ULU) announced today that it has signed a Binding Letter of Intent ("Agreement") with Exciton Technologies Inc. ("Exciton") to develop and market a product that will combine Altrazeal® with Exciton's proprietary exSALT™ Antimicrobial Technology. Read More

11/10/2010

ULURU INC. PROVIDES ALTRAZEAL® CLINICAL UPDATE - Marketing Focused on Large Chronic Wound Segments

Addison, Texas, November 10, 2010; ULURU Inc. (NYSE Amex: ULU) today provided a clinical update and summary of recent participation at major wound care conferences. Read More

11/08/2010

COMMERCIAL UPDATE - INTERNATIONAL MARKETS: Up to 10 Product Launches; Potential Revenue $1 - 1.5 Million

Addison, Texas, November 8, 2010; ULURU Inc. (NYSE Amex: ULU) today provided an update on its international commercial activities. Read More

09/30/2010

ULURU INC. ANNOUNCES COMMERCIAL EXHIBIT AND SCIENTIFIC PRESENTATIONS AT MAJOR NATIONAL WOUNDCARE MEETINGS

Addison, Texas, September 30, 2010; ULURU Inc. (NYSE Amex: ULU) announced today that the Company will have an extensive presence at the Clinical Symposium on Advances in Skin and Wound Care (“CSAWC”) which will be held on September 30 – October 3, 2010 in Orlando, Florida. Read More

08/02/2010

ULURU Inc Announces CE Mark Certification

Addison, Texas, August 2, 2010; ULURU Inc. (NYSE Amex: ULU) announced today that Altrazeal® Transforming Powder Dressing has been granted CE Mark Certification in all countries within the European Economic Area (“EEA”). Read More

06/14/2010

ULURU INC. TO EXHIBIT ALTRAZEAL™ AND SUPPORTIVE CLINICAL RESEARCH PRESENTATIONS AT 2010 WOCN/WCET JOINT CONFERENCE

Addison, Texas, June 14, 2010; ULURU Inc. (NYSE Alternext: ULU) announced today that six posters detailing clinical experience using Altrazeal™ Transforming Powder Dressing will be presented at the 2010 Joint Conference of the Wound Ostomy and Continence Nurses Society (WOCN) and World Council of Enterostomal Therapists (WCET) on June 14-16 in Phoenix, Arizona. ULURU will be present at the conference with an exhibit booth to provide education on best clinical practice with Altrazeal™ to the more than 4,500 nurse professionals attending the joint meeting who are experts in the care of patients with wound, ostomy and continence disorders. Read More

06/03/2010

ADVANCED RESEARCH AND DEVELOPMENT ON NANOFLEX APPLICATIONS IN DRUG DELIVERY PRESENTED AT 11TH ANNUAL NEW CARDIOVASCULAR HORIZONS MEETING

Addison, Texas, June 3, 2010; ULURU Inc. (NYSE Alternext: ULU) announced today that advanced applications of the Nanoflex™ technology, related to future products in drug delivery and tissue engineering, will be presented at the 11th annual New Cardiovascular Horizons Meeting to be held in New Orleans, Louisiana on June 2-5, 2010. This meeting is the largest medical meeting that focuses on peripheral artery disease and peripheral interventions, including wound care for vascular ulcers, the application of advanced therapies for limb salvage and amputation prevention. Read More

04/15/2010

ULURU INC. TO PRESENT ALTRAZEAL™ CLINICAL EVIDENCE AT THE 23rd ANNUAL SYMPOSIUM ON ADVANCED WOUND CARE AND WOUND HEALING SOCIETY (SAWC/WHS)

Addison, Texas, April 15, 2010; ULURU Inc. (NYSE Amex: ULU) announced today that the company will present clinical evidence at the 2010 joint annual meeting of the Symposium on Advanced Wound Care and the Wound Healing Society (SAWC/WHS) in Orlando, Florida, April 17-20. SAWC/WHS is the premier wound care educational program within this clinical field and is the largest annual gathering of wound care clinicians in the United States. More than 2,000 physicians, podiatrists, nurses, therapists, and researchers are expected to attend the 2010 SAWC/WHS meeting. In addition to the presentation of the clinical evidence, the Company will also be providing educational guidance, showcasing advanced research on Altrazeal™ and products in the Altrazeal™ pipeline. Read More

04/08/2010

ULURU INC. TO PRESENT ALTRAZEAL™ CLINICAL EVIDENCE AT THE 2010 AMERICAN PROFESSIONAL WOUND CARE ASSOCIATION (APWCA) NATIONAL CLINICAL CONFERENCE

Addison, Texas, April 8, 2010; ULURU Inc. (NYSE Amex: ULU) announced today that the Company will be presenting clinical data at the 2010 American Professional Wound Care Association (APWCA) National Conference in Philadelphia, PA April 8-11, 2010. At the conference, Altrazeal™ clinical evidence, best clinical practices, and advanced clinical applications will be showcased in both podium and poster presentations. Read More

03/23/2010

ULURU Inc. Sponsors Wound Dressing Workshop at the 2010 Diabetic Foot Global Conference (DFCon)

Addison, Texas, March 23, 2010; ULURU Inc. (NYSE Amex: ULU) announced that it sponsored a Wound Dressing Workshop at the 2010 Diabetic Foot Global Conference. Attendees of the Diabetic Foot Global Conference (DFCon) in Hollywood, California on March 20, 2010 participated in a hands-on workshop where they were trained in “best clinical practice” for Altrazeal™. Participants learned application techniques, clinical endpoints, and methods for treating different wound types including diabetic foot ulcers, venous stasis ulcers and pressure ulcers. The workshop was led by Dr. John Steinberg, DPM of Georgetown University Hospital. Read More

01/21/2010

ULURU INC. INVITED TO PRESENT AT RESEARCH AND NEW VENTURES FORUM ON NANOMEDICINE

Dallas, Texas, January 21, 2010; ULURU Inc. (NYSE Alternext: ULU) announced today that it will make a presentation at a forum highlighting the business of nanomedicine at the Institute for Innovation & Entrepreneurship (University of Texas, Dallas). Conference details and the program can be found at innovation.utdallas.edu. Read More

12/09/2009

ULURU INC. INVITED TO PRESENT ALTRAZEAL™ RESEARCH AT 10th ANNUAL WOUND HEALING SCIENCE AND INDUSTRY CONFERENCE

Addison, Texas, December 9, 2009; ULURU Inc. (NYSE Alternext: ULU) announced today that a presentation on Altrazeal™ Transforming Powder Dressing will be made at the prestigious 10th Annual Wound Healing Science and Industry Conference to be held December 10-13, 2009 in St. Thomas, U.S. Virgin Islands. The presentation will include research on advanced applications of Altrazeal™ related to the development of future products in drug delivery and tissue engineering. This conference is organized as a collaborative series of symposia and poster presentations with many of the top scientists and clinicians in the field of wound care discussing advanced research and treatments. Conference details and the program can be found at www.stthomaswoundhealing.com. Read More

12/03/2009

ULURU INC. OBTAINS STATUS OF APPROVED SUPPLIER WITH MCKESSON

Addison, Texas, December 3, 2009; ULURU Inc. (NYSE Alternext: ULU) announced today that McKesson Medical-Surgical, Inc., one of the major pharmaceutical distributors in the United States, has approved ULURU Inc. to be one of its suppliers and has placed its first significant order for Altrazeal™. McKesson Medical-Surgical delivers a comprehensive offering of medical-surgical supplies, medical equipment and health care technology-related services to the alternate site market, including physician offices, surgery centers, long-term care facilities and home care businesses throughout the United States. Read More

10/22/2009

ULURU INC. ANNOUNCES POSTER PRESENTATION ON THE USE OF ALTRAZEAL™ IN HOME CARE

Addison, Texas, October 22, 2009; ULURU Inc. (NYSE Alternext: ULU) today announced that a poster highlighting the benefits of using Altrazeal™ in the home care market segment will be among the Altrazeal™ posters being presented at the 24th Annual "Clinical Symposium on Advances in Skin and Wound Care" in San Antonio, Texas from October 22-25. Read More

10/21/2009

ULURU INC. ANNOUNCES EXTENSIVE CLINICAL EVIDENCE PRESENTED AT THE 24TH ANNUAL 'CLINICAL SYMPOSIUM ON ADVANCES IN SKIN AND WOUND CARE'

Addison, Texas, October 21, 2009; ULURU Inc. (NYSE Alternext: ULU) today announced that there will be 16 poster presentations featuring clinical and pharmacoeconomic results at the 24th Annual “Clinical Symposium on Advances in Skin and Wound Care” to be held in San Antonio, Texas from October 22-25. Read More

09/16/2009

ULURU INC. PRESENTS RESULTS OF FIRST RANDOMIZED CLINICAL TRIAL FOR ALTRAZEAL™ AT THE SYMPOSIUM ON ADVANCED WOUND CARE (SAWC) FALL MEETING IN WASHINGTON D.C.

Addison, Texas, September 16, 2009; ULURU Inc. (NYSE Alternext: ULU) announced today the presentation of results from the first completed randomized clinical trial for Altrazeal at the SAWC Fall symposium in Washington D.C. September 16-18. The recently completed clinical study compared healing, pain and comfort of skin graft donor sites treated with either AltrazealTM or with a leading commercial sodium carboxymethylcellulose-silver ("CMC-Ag") dressing. Read More

07/29/2009

ULURU INC TO PRESENT ALTRAZEAL™ CLINICAL EVIDENCE AT THE AMERICAN PODIATRIC MEDICAL ASSOCIATION (APMA) ANNUAL SCIENTIFIC MEETING IN TORONTO, CANADA

Addison, Texas, July 29, 2009; ULURU Inc. (NYSE Alternext: ULU) announced today that the application of Altrazeal™ and best clinical practice will be demonstrated in a hands-on Wound Care Pre Conference Workshop at the APMA Annual Scientific Meeting July 28 - August 2. In addition, clinical evidence on the treatment of wounds using Altrazeal™ Transforming Powder Dressing will be presented on posters during the meeting. Read More

05/05/2009

ULURU Inc. announces ALTRAZEAL™ Clinical Experience Published in the International Wound Journal

Addison, Texas, May 5, 2009; ULURU Inc. (NYSE AMEX: ULU) announced today that clinical evidence utilizing Altrazeal™ Nanoflex Transforming Powder Dressing has been published in the respected peer-reviewed publication, International Wound Journal. The article, which is the first peer-review publication detailing clinical experience using Altrazeal™, was authored by a team of clinicians and scientists working at Southern Arizona Limb Salvage Alliance (“SALSA”) at the University of Arizona College of Medicine, located in Tucson, Arizona. Read More

04/23/2009

ULURU to present Clinical Evidence and Advanced Research on ALTRAZEAL at the Society for Advance Wound Care Conference for 2009

Addison, Texas, April 23, 2009; ULURU Inc. (NYSE AMEX: ULU) announced today that clinical evidence on the treatment of wounds using Altrazeal™ along with pre-clinical and physical data on Altrazeal™ and Altrazeal™ Silver will be presented at the annual Society for Advance Wound Care Conference (“SAWC”) being held in Grapevine, Texas, April 26-30, 2009. The clinical evidence and data will be presented on posters on display during the meeting. Read More

04/01/2009

ALTRAZEAL™ Clinical Evidence to be prepared at the American Professional Wound Care Association (APWCA)

Addison, Texas, April 1, 2009; ULURU Inc. (NYSE Alternext: ULU) announced today that clinical evidence on the treatment of wounds using Altrazeal™ Transforming Powder Dressing, and data on the physical properties of Altrazeal™ Silver will be presented at the annual APWCA National Clinical Conference in Philadelphia, April 2-5, 2009. The work will be presented in podium presentations and with posters on display during the meeting. Read More.

03/13/2009

ULURU INC. Announces Appointment of Jeffrey A. Niezgoda

Addison, Texas, March 13, 2009; ULURU Inc. (NYSE Alternext: ULU) today announced the appointment of Jeffrey A. Niezgoda, MD, FACHM, FACEP, FAPWCA as Chairman of the Company’s Scientific Advisory Board. Currently, Dr. Jeffrey Niezgoda is the Medical Director of The Centers for Comprehensive Wound Care and Hyperbaric Oxygen Therapy, St. Luke's Medical Center, Aurora Health Care, in Milwaukee, Wisconsin. Read More.

03/13/2009

ULURU INC. to Present at the Diabetic Foot Global Conference

Addison, Texas, March 13, 2009; ULURU Inc. (NYSE Alternext: ULU) announced that clinical evidence on the treatment of diabetic foot ulcers, and data on the use of its patented Nanoflex™ Technology for Therapeutic Delivery will be presented at the annual DFCon Global Meeting in Los Angeles, California March 19-21. The work will be presented on posters that will be on display during the meeting. Read More.

11/04/2008

ULURU INC. ANNOUNCES THE LAUNCH OF THE Altrazeal™ WEBSITE

Addison, Texas, November 4, 2008; ULURU Inc. (NYSE Alternext: ULU) today announced that it has launched a new Altrazeal™ website designed to provide information to both health care professionals and patients on the clinical benefits of Altrazeal™.

10/30/2008

ULURU INC. HOSTS SYMPOSIUM ON Altrazeal™ AT THE 23RD ANNUAL CLINICAL SYMPOSIUM ON ADVANCES IN SKIN & WOUND CARE

Las Vegas, NV, October 30, 2008; ULURU Inc. (NYSE Alternext: ULU) – Clinical updates and new case studies on the application of Altrazeal™ - Transforming Powder Dressing were presented yesterday at a special session of this year's annual Clinical Symposium on Advances in Skin & Wound Care. The session was hosted by ULURU Inc.

10/28/2008

ULURU INC. ANNOUNCES POSTER PRESENTATIONS AT THE 23RD ANNUAL “CLINICAL SYMPOSIUM ON ADVANCES IN SKIN & WOUND CARE”

Addison, Texas, October 28, 2008; ULURU Inc. (NYSE Alternext: ULU) today announced that it will present two posters at the “Clinical Symposium on Advances in Skin and Wound Care” being held in Las Vegas from October 27 to October 30, 2008.

10/21/2008

ULURU INC. ANNOUNCES THE COMMENCEMENT OF FIRST CLINICAL STUDY USING ALTRAZEAL™ SILVER - Multi-Center Study in Skin Graft Donor Site Patients

Addison, Texas, October 21, 2008; ULURU Inc. (NYSE Alternext: ULU) today announced that it has commenced a clinical study to evaluate patients with graft donor sites treated with ALTRAZEAL Silver compared with a market leading silver containing carboxymethylcellulose dressing. The study will be conducted at four clinical sites with 40 evaluable patients being enrolled. The first study site has been initiated and the Company plans to initiate additional sites within the next 30-days.

10/13/2008

ULURU Inc. to Host Satellite Symposium at the 23rd Annual 'Clinical Symposium on Advances in Skin & Wound Care'

ADDISON, Texas, Oct. 13, ULURU, Inc. (NYSE Alternext: ULU) today announced that it will be sponsoring a Satellite Symposium titled "ALTRAZEAL - Transforming Clinical Wound Management - from Science to Outcomes With An Innovative Powder Dressing" on October 29, 2008 at 7 a.m. at the "Clinical Symposium On Advances in Skin and Wound Care" being held in Las Vegas.

09/30/2008

ULURU Inc. Announces the Filing of a 510k Submission with the FDA for ALTRAZEAL Silver

ADDISON, Texas, Sept. 30, ULURU, Inc. (Amex: ULU) today announced that it has filed a 510k application with the United States Food and Drug Administration (FDA) for ALTRAZEAL Silver. Preclinical studies conducted to support the filing have shown that superior healing rates in numerous porcine wound models have been achieved relative to competitive silver dressings.

05/19/2008

ULURU INC. Announces the Launch Plan for ALTRAZEAL™

Addison, Texas, May 8, 2008; ULURU Inc. (AMEX. ULU) today announced the Company’s launch plan for ALTRAZEAL and the commercial availability of the product commencing the week of May 19, 2008. ALTRAZEAL is the first wound care dressing to be developed from our nanoparticles™ aggregate technology. It is an easy to apply and remove powder hydrogel that in the presence of body fluids rapidly converts to a gel material which fills and seals the wound, promoting an optimal moist healing environment and reduces the need for multiple dressing changes. Read More

02/20/2008

ULURU INC. Provides Details on ALTRAZEAL™ Launch

Addison, Texas, February 20, 2008; ULURU Inc. (AMEX: ULU) today provided an update on the status of its wound care franchise. In preparation for the launch of ALTRAZEAL our first wound care product, which is scheduled to occur in the second quarter 2008, the Company is conducting numerous market research surveys. Read More.